DKK2452 -10.0 -0.4%
Last Trade - 16/04/21
| Market Cap | £3.12bn |
| Enterprise Value | £3.20bn |
| Revenue | £406.8m |
| Position in Universe | 179th / 1831 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,569 | 3,005 | 2,910 | 2,915 | 3,274 | 3,491 | 3,858 | 4,364 | +6.3% | ||
| +64.8 | -22.4 | +81.2 | +333.7 | |||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 9, 1961 |
| Public Since | January 1, 1961 |
| No. of Shareholders: | 17,697 |
| No. of Employees: | 2,447 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange - Copenhagen |
| Shares in Issue | 10,928,323 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Boege Alle 1, HOERSHOLM, 2970, Denmark |
| Web | https://www.alk.net/ |
| Phone | +45 45 747576 |
| Contact | Per Plotnikof (Vice President Corporate Communications, Investor Relations and Strategic Planning) |
| Auditors | PricewaterhouseCoopers |
As of 16/04/21, shares in ALK-Abello A/S are trading at DKK2452, giving the company a market capitalisation of £3.12bn. This share price information is delayed by 15 minutes.
Shares in ALK-Abello A/S are currently trading at DKK2452 and the price has moved by 40.92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ALK-Abello A/S price has moved by 9.2% over the past year.
Of the analysts with advisory recommendations for ALK-Abello A/S, there are there are currently 3 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ALK-Abello A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ALK-Abello A/S is scheduled to issue upcoming financial results on the following dates:
ALK-Abello A/S does not currently pay a dividend.
ALK-Abello A/S does not currently pay a dividend.
ALK-Abello A/S does not currently pay a dividend.
To buy shares in ALK-Abello A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in ALK-Abello A/S are currently trading at DKK2452, giving the company a market capitalisation of £3.12bn.
Here are the trading details for ALK-Abello A/S:
Based on an overall assessment of its quality, value and momentum, ALK-Abello A/S is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in ALK-Abello A/S are currently priced at DKK2452. At that level they are trading at 21.08% discount to the analyst consensus target price of 0.00.
Analysts covering ALK-Abello A/S currently have a consensus Earnings Per Share (EPS) forecast of 8.298 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ALK-Abello A/S. Over the past six months, the relative strength of its shares against the market has been -4.47%. At the current price of DKK2452, shares in ALK-Abello A/S are trading at 10.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ALK-Abello A/S PE ratio based on its reported earnings over the past 12 months is 0.535k. The shares are currently trading at DKK2452.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ALK-Abello A/S's management team is headed by:
Here are the top five shareholders of ALK-Abello A/S based on the size of their shareholding:
